Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
Azevan Pharmaceuticals · Aggressive Behavior in Fragile X Syndome
Phase 2
Not yet recruiting
80
2026-01
Industry sponsor intelligence
Azevan PharmaceuticalsClinical Pipeline.
Lead-sponsor view of Azevan Pharmaceuticals's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 1
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 80
Pipeline overview
Programs by phase and activity.
Velocity
Azevan Pharmaceuticals trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Vasopressin → | 1 | 0 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Azevan Pharmaceuticals studies.
This page groups studies where Azevan Pharmaceuticals is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates